Bulletin
Investor Alert

New York Markets Open in:

CymaBay Therapeutics Inc.

NAS: CBAY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 18, 2020, 7:52 p.m.

/zigman2/quotes/201917619/composite

$

6.88

Change

-0.04 -0.58%

Volume

Volume 55,805

Quotes are delayed by 20 min

/zigman2/quotes/201917619/composite

Previous close

$ 6.55

$ 6.92

Change

+0.37 +5.65%

Day low

Day high

$6.52

$6.95

Open

52 week low

52 week high

$1.21

$7.09

Open

Annual Financials for CymaBay Therapeutics Inc.

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue --10M--
Cost of Goods Sold (COGS) incl. D&A 22,00029,000-105,000800,000
COGS excluding D&A -----
Depreciation & Amortization Expense 22,00029,00035,000105,000800,000
Depreciation 22,00029,00035,000105,000800,000
Amortization of Intangibles -----
Gross Income (22,000)(29,000)-(105,000)(800,000)
20152016201720182019 5-year trend
SG&A Expense 25.88M25.56M31.29M72.4M102.28M
Research & Development 17.03M15.94M18.94M58.12M83.84M
Other SG&A 8.85M9.62M12.35M14.28M18.44M
Other Operating Expense -----
Unusual Expense (11.12M)(76,000)5.77M407,0005.08M
EBIT after Unusual Expense (14.78M)(25.51M)(27.1M)(72.91M)(108.15M)
Non Operating Income/Expense ---(3.29M)-
Non-Operating Interest Income 160,000176,000621,0003.99M5.34M
Equity in Affiliates (Pretax) -----
Interest Expense 913,0001.34M1.08M336,000-
Gross Interest Expense 913,0001.34M1.08M336,000-
Interest Capitalized -----
Pretax Income (15.53M)(26.67M)(27.56M)(72.55M)(102.81M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (15.53M)(26.67M)(27.56M)(72.55M)(102.81M)
Minority Interest Expense -----
Net Income (15.53M)(26.67M)(27.56M)(72.55M)(102.81M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (15.53M)(26.67M)(27.56M)(72.55M)(102.81M)
Preferred Dividends -----
Net Income Available to Common (15.53M)(26.67M)(27.56M)(72.55M)(102.81M)
EPS (Basic) (0.82)(1.14)(0.79)(1.26)(1.53)
Basic Shares Outstanding 18.9M23.45M34.9M57.81M67.03M
EPS (Diluted) (0.83)(1.14)(0.79)(1.26)(1.53)
Diluted Shares Outstanding 18.9M23.45M34.9M57.81M67.03M
EBITDA (25.88M)(25.56M)(21.29M)(72.4M)(102.28M)
Link to MarketWatch's Slice.